西格列汀片与格列美脲片治疗初发2型糖尿病伴非酒精性脂肪肝的疗效比较  

Comparison of the Effect between Sitagliptin and Glimepiride in the Treatment of Newly Diagnosed Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease

作　　者：肖毅[1] 徐谷根[1] 尹卓娜[1] 赵红莉[1] 沈洁[2] XIAO Yi XU Gu-gen YIN Zhuo-na ZHAO Hong-li SHEN Jie(Department of Endocrinology, Guangdong No.2 Provincial People＇s Hospital, Guangzhou, Guangdong, 510317, China Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, 510000, China)

机构地区：[1]广东省第二人民医院内分泌科,广东广州510317 [2]南方医科大学第三附属医院内分泌代谢科,广东广州510000

出　　处：《现代生物医学进展》2016年第36期7190-7193,共4页Progress in Modern Biomedicine

摘　　要：目的：比较西格列汀片与格列美脲片治疗初发2型糖尿病伴非酒精性脂肪肝（NAFLD）的疗效。方法：选取2014年7月~2015年7月间在我院治疗的初发2型糖尿病伴NAFLD患者78例,通过随机数字表法分为观察组及对照组,各39例。对照组在常规治疗的基础上加用格列美脲片,观察组在常规治疗的基础上加用西格列汀片。治疗后对两组患者脂肪肝的疗效进行评价,比较治疗前及治疗12周后两组患者血糖、血脂、肝功能相关指标水平,并观察两组治疗过程中的不良反应。结果：观察组患者总有效率为84.62%,高于对照组的71.49%（P〈0.05）。治疗12周后,两组患者血糖、血脂、肝功能相关指标水平均较治疗前改善,且观察谷草转氨酶（AST）、谷丙转氨酶（ALT）、谷氨酰转肽酶（GGT）水平及胰岛素抵抗指数（HOMA-IR）均优于对照组,差异均有统计学意义（均P〈0.05）。两组患者不良反应发生率比较,差异无统计学意义（P〉0.05）。结论：采用西格列汀片治疗初发2型糖尿病伴NAFLD可有效控制患者脂肪肝症状,保护肝功能,相比格列美脲片疗效更好,值得进一步推广使用。Objective： To compare the effect of sitagliptin and glimepiride in the treatment of newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease （NAFLD）. Methods： Selected July 2014 to July 2015 in our hospital treatment of 78 patients newly diagnosed type 2 diabetic with NAFLD, randomly divided into the observation group and control group, 39 cases in each. The control group on the basis of conventional therapy plus glimepiride. Observation group on the basis of conventional therapy plus sitagliptin. After treatment, evaluated the efficacy of two groups of patients with fatty liver, compared two groups of patients before and after 12 weeks of treatment of blood glucose, blood lipid and liver function indexes, and adverse reactions were compared between the two groups during the treatment process. Results： The total efficiency of the observation group was 84.62%, higher than 71.49% in the control group （P〈0.05）. After 12 weeks of treatment, the blood glucose, blood lipid and liver function indexes improved than before treatment, and aspartate aminotransferase （AST）, and alanine aminotransferase （ALT）, glutamyl-transpeptidase （GGT）level and insulin resistance index（HOMA-IR）in observation group were better than the control group, differences were statistical significant（P〈0.05）. Two groups of patients with adverse reaction rate comparison, the difference was not statistically significant （P〉0.05）. Conclusion： Using sitagliptin in the treatment of newly diagnosed type 2 diabetes with NAFLD can effectively control the symptoms of fatty liver, protect liver function, the curative effect is better than Glimepiride Tablets which is worth further promotion.

关 键 词：西格列汀片 格列美脲片 2型糖尿病 非酒精性脂肪肝 

分 类 号：R587.2[医药卫生—内分泌]